tie2 Antibody

What is the structure of the Tie2 receptor and how does it influence antibody binding?

The Tie2 receptor possesses a complex extracellular domain (ECD) structure that directly impacts antibody binding mechanisms. The ECD contains three immunoglobulin (Ig) domains, three epidermal growth factor (EGF) domains, and three fibronectin type III (Fn) domains (designated Fn1, Fn2, and Fn3), followed by a single-pass transmembrane domain, a cytoplasmic protein tyrosine kinase domain, and a C-terminal tail . Different antibodies target distinct epitopes on this structure - for example, the humanized Tie2-agonistic antibody (hTAAB) specifically targets the membrane-proximal Fn3 domain, which is structurally distinct from the angiopoietin binding site . This structural arrangement allows for multiple potential antibody binding strategies, including those that compete with natural ligands and those that function through ligand-independent mechanisms.

How do natural ligands and antibodies differ in their Tie2 activation mechanisms?

Natural ligands like angiopoietin-1 (Ang1) activate Tie2 through induced oligomerization, while antibodies can activate Tie2 through various mechanisms depending on their structure and binding epitopes. Ang1, a multimeric secreted glycoprotein, binds to Tie2 and induces receptor oligomerization and subsequent auto-phosphorylation, activating downstream pathways including Akt phosphorylation (promoting anti-apoptotic activity) and suppression of Src signaling (inhibiting vascular permeability) .

In contrast, antibody-based activation mechanisms vary significantly. For instance, the 4E2 antibody binds Tie2 with nanomolar affinity in a ligand-independent manner while partially inhibiting Ang1 binding and completely blocking Ang2 binding, suggesting shared binding epitopes . The engineered tetra-valent antibody ASP4021 mimics Ang1's multimeric structure, providing similar activation potency by facilitating Tie2 dimerization or multimerization . The molecular architecture of these antibodies is critical for their function—monomer antibodies generally show weak agonistic activity, while dimer and higher multimeric forms demonstrate significantly stronger activation potential .

What experimental controls should be included when validating a new Tie2 antibody?

When validating a new Tie2 antibody, comprehensive control experiments are essential for establishing specificity, functionality, and comparative efficacy. These should include:

• Binding specificity controls: Test binding to related receptors (particularly Tie1) to confirm target selectivity. For example, ASP4021 developers used direct ELISA to demonstrate that while the antibody bound to Tie2 with high affinity, it showed no binding to human Tie1 .

• Cross-reactivity assessment: Evaluate binding across species (human, mouse, rat, and non-human primates) using surface plasmon resonance or similar techniques. ASP4021 demonstrated comparable binding constants across species (KD ≈ 1.0-1.5 × 10^-9 mol/L) .

• Natural ligand competition assays: Assess whether the antibody competes with Ang1 and/or Ang2 for Tie2 binding, providing insight into the binding epitope. This can be performed using competitive binding assays with labeled angiopoietins .

• Functional validation in cellular models: Compare antibody-induced Tie2 phosphorylation and downstream signaling activation to those produced by natural ligands like Ang1 .

• Concentration-response curves: Generate dose-dependent activity profiles in relevant cell types to determine EC50 values and compare potency with reference antibodies and natural ligands .

These controls establish both mechanistic understanding and functional reliability of new Tie2-targeting antibodies.

What cell systems are most appropriate for studying Tie2 antibody effects in vitro?

The selection of appropriate cell systems is crucial for investigating Tie2 antibody activity, with several validated models providing complementary insights:

Human Endothelial Cell Lines: Primary human umbilical vein endothelial cells (HUVECs) and human dermal microvascular endothelial cells (HDMECs) provide physiologically relevant systems for studying Tie2 signaling in its native cellular context . Patient-derived endothelial cells from conditions like Clarkson disease (ISCLS) offer unique models for studying disease-specific Tie2 antibody responses .

Engineered Expression Systems: Tie2-expressing Ba/F3 cells (a murine pro-B cell line engineered to express human Tie2) serve as a clean system for evaluating antibody-induced receptor activation and downstream effects on cell viability . CHO cells expressing Tie2 provide another platform for antibody binding and functional studies .

When selecting cell systems, researchers should consider key methodological requirements:

• Stable Tie2 expression levels (verified by Western blot or flow cytometry)

• Preservation of normal signaling pathway components

• Reproducible responses to reference Tie2 ligands (Ang1/Ang2)

• Appropriate for the specific assay endpoints (barrier function, cell survival, migration, etc.)

For production of therapeutic-grade Tie2 antibodies, both 293 and CHO cell systems have demonstrated capability for stable expression and appropriate post-translational modifications .

How should researchers assess Tie2 activation in response to antibody treatment?

Comprehensive assessment of Tie2 activation requires multi-parameter analysis at the molecular, cellular, and functional levels:

Receptor Phosphorylation Analysis:

• Western blotting with phospho-specific antibodies targeting key tyrosine residues in the Tie2 kinase domain

• Immunoprecipitation followed by phospho-tyrosine detection

• Phospho-flow cytometry for single-cell resolution of activation status

Downstream Signaling Events:

• Akt phosphorylation (Ser473) as a key pro-survival marker

• Src inhibition as an indicator of vascular barrier enhancement

• eNOS (endothelial nitric oxide synthase) activation for vasodilatory function

Functional Readouts:

• Trans-endothelial electrical resistance (TEER) measurements to assess barrier integrity

• In vitro angiogenesis assays (tube formation, sprouting)

• Cell survival under stress conditions (serum deprivation, inflammatory challenges)

Researchers should employ time-course experiments to capture both rapid (minutes to hours) and sustained (hours to days) signaling responses, as these may have distinct physiological implications. Additionally, comparison with known Tie2 agonists (Ang1/COMP-Ang1) and antagonists (Ang2) at standardized concentrations provides critical reference points for interpreting antibody effects .

What are the key considerations for developing a tetra-valent Tie2 antibody?

Developing an effective tetra-valent Tie2 antibody requires careful consideration of multiple design elements that directly impact its functionality and manufacturability:

Structural Design Principles:

• Antibody fragment arrangement: The tetra-valent format consisting of two heavy chains and four light chains, with each heavy chain comprising two structures (one with VH-CH1 and another with VH-CH1-CH2-CH3) .

• Linker optimization: Testing different linker sequences (e.g., IgG1 upper hinge sequence-based linker EPKSCGS, IgG3 upper hinge sequence-based linkers) to maintain optimal spatial orientation of binding domains .

• Fc modifications: Introducing amino acid mutations (e.g., L234A, L235A, P331S) in the heavy chain constant region to reduce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity when targeting cell surface receptors like Tie2 .

Production Considerations:

• Expression system selection: Both CHO and 293 cell systems have successfully produced stable tetra-valent Tie2 antibodies .

• Purification strategy: Sequential affinity chromatography and size exclusion chromatography (SEC) to ensure homogeneity and removal of incompletely assembled antibodies .

• Quality control: SDS-PAGE under reducing and non-reducing conditions to confirm expected molecular weight and structural integrity .

Functional Validation:

• Binding affinity comparison with natural ligands using surface plasmon resonance

• Cross-reactivity testing across species (human, mouse, rat, monkey)

• Comparative agonistic activity assessment between tetra-valent, bivalent, and natural ligands in Tie2-expressing cellular models

The tetra-valency has proven crucial for full agonistic activity by facilitating Tie2 receptor dimerization or multimerization, which is essential for subsequent auto-phosphorylation and downstream signaling activation .

How does the valency of Tie2 antibodies impact receptor clustering and activation?

The valency of Tie2 antibodies plays a decisive role in receptor clustering and activation, with significant implications for signaling potency and physiological outcomes. Research has established a clear hierarchy of effectiveness based on antibody valency:

Monovalent vs. Multivalent Comparison:

• Monovalent antibodies (single Fab fragments) demonstrate minimal agonistic activity due to their inability to cross-link Tie2 receptors effectively .

• Bivalent antibodies (conventional IgG structure) show moderate activity but significantly less potent than their higher-valency counterparts .

• Tetravalent and higher multimeric antibodies exhibit potent agonistic activity comparable to the natural ligand Ang1 .

This valency-dependent activation pattern correlates directly with the mechanism of Tie2 activation, which requires receptor clustering for autophosphorylation. The tetravalent arrangement appears optimal for mimicking the natural clustering induced by the multimeric Ang1 ligand .

Research with the engineered tetravalent antibody ASP4021 demonstrated that while bivalent antibody 2-16A2 (purified as a monomer) showed weak agonistic activity in Tie2-expressing Ba/F3 cells, the tetravalent versions of the same antibody clone (TIE-1-Igγ1-WT and ASP4021) exhibited significantly higher potency comparable to Ang1 . This finding confirms that the tetravalent structure facilitates the critical Tie2 dimerization or multimerization required for receptor activation.

What signaling pathways are activated by different Tie2 antibodies compared to natural ligands?

Tie2 antibodies can activate various downstream signaling pathways with important distinctions from natural ligand activation profiles:

Primary Signaling Pathways Activated:

• PI3K/Akt Pathway: Both natural ligands (Ang1) and agonistic antibodies activate this pro-survival pathway in endothelial cells. Ang1 binding to Tie2 induces Akt phosphorylation, promoting anti-apoptotic activity . Similarly, the tetravalent antibody ASP4021 demonstrated comparable activation of this pathway, supporting endothelial cell survival .

• Src Inhibition Pathway: Tie2 activation by Ang1 suppresses Src signaling, which is critical for inhibiting vascular permeability . The 4E2 antibody demonstrated effectiveness in reducing baseline and proinflammatory mediator-induced barrier dysfunction in ISCLS patient-derived endothelial cells, suggesting successful modulation of this pathway .

• eNOS Pathway: Activation of Tie2 in vascular endothelial cells by Ang1 induces vasodilation and enhances blood flow via nitric oxide production . Agonistic antibodies like ASP4021 may similarly activate this pathway, though with potentially different kinetics or magnitude.

Pathway-Specific Differences:

The epitope targeted by different antibodies can lead to distinct pathway activation profiles. For example, antibodies binding to the Fn3 domain (like hTAAB) may initiate signaling cascades with different kinetics or emphasis compared to those that compete directly with Ang1/Ang2 at their binding sites . Additionally, tetravalent antibodies like ASP4021 appear to more faithfully recapitulate the broad pathway activation profile of the natural ligand Ang1 compared to bivalent formats .

When designing experiments to characterize pathway activation, researchers should employ time-course studies with multiple readouts to capture the full spectrum of signaling events triggered by different antibody formats.

How do Tie2 antibodies interact with the Ang1/Ang2 axis in regulating vascular function?

Tie2 antibodies demonstrate complex interactions with the Ang1/Ang2 regulatory axis that can be leveraged for specific therapeutic outcomes:

Competition vs. Coexistence Mechanisms:

Some Tie2 antibodies, like 4E2, demonstrate partial inhibition of Ang1 binding and complete blockade of Ang2 binding, suggesting they share binding epitopes with these natural ligands . This competitive interaction has significant functional implications, as it can:

• Displace the antagonistic Ang2 from Tie2, potentially reversing its inhibitory effects

• Partially compete with Ang1, potentially modulating its effects

• Create a net agonistic environment by shifting the Ang1/Ang2 balance

Other antibodies, such as hTAAB, bind to epitopes distinct from the angiopoietin binding sites (e.g., the Fn3 domain), allowing for potential co-binding and synergistic effects with Ang1 .

Resistance to Ang2 Antagonism:

A particularly valuable property of certain Tie2 antibodies is their ability to activate the receptor despite the presence of the antagonistic Ang2. The polygonal Tie2 clustering induced by hTAAB has been shown to be resistant to antagonism by Ang2 . This property is especially relevant in pathological conditions where Ang2 levels are elevated, such as diabetic retinopathy .

Context-Dependent Effects:

The interaction between Tie2 antibodies and the Ang1/Ang2 axis may vary depending on:

• The relative concentrations of Ang1 and Ang2 in the local environment

• The specific vascular bed being studied (as angiopoietin expression varies by tissue)

• Disease state (inflammatory conditions often increase Ang2 expression)

• The binding affinity of the antibody relative to the natural ligands

Understanding these complex interactions is crucial for predicting antibody efficacy in different physiological and pathological contexts.

How effective are Tie2 antibodies in models of vascular leakage disorders?

Tie2 antibodies have demonstrated significant efficacy in multiple models of vascular leakage disorders, with particularly promising results in Clarkson disease (also known as Idiopathic Systemic Capillary Leak Syndrome or ISCLS):

Clarkson Disease Models:
The monoclonal antibody 4E2, which specifically targets the endothelial receptor tyrosine kinase Tie2, showed remarkable efficacy in both cellular and animal models of ISCLS. In ISCLS patient-derived endothelial cells, 4E2 activated Tie2 and significantly reduced both baseline and proinflammatory mediator-induced barrier dysfunction . In the SJL/J mouse model of ISCLS, 4E2 reduced mortality and vascular leakage associated with systemic histamine challenge or influenza infection . These findings strongly support a critical role for Tie2 dysregulation in ISCLS pathophysiology and highlight the therapeutic potential of Tie2-activating antibodies.

Mustard Oil-Induced Vascular Permeability Model:
The engineered tetravalent antibody ASP4021 demonstrated significant efficacy in an acute model of vascular leakage. A single subcutaneous administration of ASP4021 substantially suppressed mustard oil-induced vascular permeability in rats . This rapid effect on an established model of acute inflammatory vascular leakage suggests broad potential applications beyond chronic vascular disorders.

Mechanistic Insights:
The efficacy of Tie2 antibodies in these models appears to be mediated through several complementary mechanisms:

• Strengthening endothelial tight junctions through Src inhibition

• Promoting endothelial cell survival during inflammatory stress

• Counteracting the effects of elevated Ang2 (which is often increased during inflammation)

These findings collectively suggest that Tie2-activating antibodies represent a promising therapeutic approach for disorders characterized by pathological vascular leakage, potentially addressing an unmet medical need in conditions where mortality from acute flares approaches 30% due to lack of effective therapies .

What are the key differences between in vitro and in vivo findings with Tie2 antibodies?

Understanding the translation from in vitro to in vivo settings is critical for accurate interpretation of Tie2 antibody research:

Pharmacokinetic Considerations:
In vitro studies typically maintain constant antibody concentrations, while in vivo applications must contend with distribution, metabolism, and clearance factors. Engineered tetravalent antibodies like ASP4021 have demonstrated favorable pharmacokinetic properties in rats and non-human primates , suggesting potential for once-weekly or less frequent dosing in clinical applications—a significant advantage over recombinant Ang1 variants with shorter half-lives.

Cell Type Interactions:
While in vitro studies often focus on isolated endothelial cells, in vivo environments include multiple cell types that interact with the vascular endothelium. Tie2 is expressed not only on endothelial cells but also on some hematopoietic stem cells and pericytes , creating potential for complex multi-cellular responses that may not be captured in simplified in vitro systems.

Disease Model Complexity:
The SJL/J mouse model of ISCLS revealed that 4E2 administration reduced mortality and vascular leakage associated with systemic histamine challenge or influenza infection . These findings highlight how the complex inflammatory milieu in disease models may reveal antibody effects not observed in baseline in vitro conditions.

Tissue-Specific Responses:
Different vascular beds show varying sensitivity to Tie2 modulation in vivo. The mustard oil-induced vascular permeability model demonstrated that ASP4021 could effectively reduce acute inflammatory vascular leakage , but this effect may vary in magnitude across different tissues and organs based on their baseline Tie2 expression and angiopoietin levels.

When designing translational research with Tie2 antibodies, investigators should incorporate appropriate in vitro assays that mimic key aspects of the in vivo microenvironment (co-culture systems, flow conditions, inflammatory stimuli) to better predict in vivo efficacy.

How might Tie2 antibodies be utilized in combination therapy approaches?

Tie2 antibodies offer promising potential in combination therapy strategies across multiple disease contexts:

Combination with Anti-Angiogenic Agents:
Tie2-activating antibodies could potentially complement VEGF inhibitors in conditions like diabetic retinopathy. While VEGF inhibitors reduce pathological angiogenesis, they may destabilize existing vessels. Concurrent Tie2 activation could promote vascular stabilization through:

• Strengthening endothelial junctions

• Enhancing pericyte recruitment and retention

• Reducing inflammation-induced vascular leakage

Adjunctive Therapy in Ischemic Conditions:
For critical limb ischemia and other ischemic disorders, combining Tie2 antibodies with existing treatments may provide synergistic benefits:

• With prostaglandin E1: Tie2 activation could enhance vasodilation effects

• With platelet inhibitors: Tie2 activation could improve endothelial function while antiplatelet agents address thrombotic risk

• With revascularization procedures: Pre-treatment with Tie2 antibodies might improve outcomes by preparing the vascular bed

Inflammatory Disease Management:
In conditions characterized by both inflammation and vascular dysfunction, such as ISCLS (Clarkson disease), combining Tie2 antibodies with immunomodulatory agents could address multiple aspects of pathophysiology:

• Tie2 antibodies directly stabilize the endothelial barrier

• Anti-inflammatory agents reduce the triggers of vascular leakage

• This dual approach may reduce mortality during acute flares, which approaches 30% with current therapies

Design Considerations for Combination Studies:

• Sequence optimization: Determining whether Tie2 antibodies should be administered before, simultaneously with, or after companion therapeutics

• Dose adjustment: Potential for dose reduction of individual agents when used in combination

• Biomarker monitoring: Identifying complementary biomarkers to track efficacy of combination therapy

The rational design of such combination approaches should be guided by mechanistic understanding of how Tie2 signaling interacts with other therapeutic targets in specific disease contexts.

How do structural modifications of Tie2 antibodies influence their pharmacodynamic properties?

Structural engineering of Tie2 antibodies presents a sophisticated approach to fine-tuning their pharmacodynamic profiles for specific therapeutic applications:

Valency Engineering:
The transition from bivalent to tetravalent formats has demonstrated dramatic improvements in agonistic potency . Research suggests that higher valency formats more effectively mimic the clustering effects of the natural ligand Ang1. Future research might explore:

• Trivalent formats for intermediate activation profiles

• Hexavalent or higher valency formats for potentially enhanced potency

• Asymmetric valency designs that combine different binding epitopes

Linker Optimization:
The linker connecting antibody domains plays a critical role in determining spatial orientation and flexibility. Studies with ASP4021 evaluated various linker sequences including IgG1 upper hinge sequence-based linker EPKSCGS, IgG3 upper hinge sequence-based linker ELKTPLGDTTHTGS, and extended versions with (GGGGS)×10 repeats . While these showed equivalent efficacy in initial testing, systematic structure-function studies might reveal subtle differences in:

• Onset of action

• Duration of receptor activation

• Resistance to proteolytic degradation

• Tissue penetration and distribution

Fc Modifications:
Strategic modifications to the Fc region can dramatically alter antibody behavior in vivo. The L234A, L235A, and P331S mutations introduced into ASP4021 were designed to reduce antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity . Additional Fc engineering approaches might include:

• Half-life extension through FcRn binding enhancements

• Tissue-specific targeting through glycoengineering

• Inflammation-responsive activity through conditional activation domains

Binding Epitope Selection:
Different antibodies target distinct epitopes on Tie2, with hTAAB binding the Fn3 domain while others may compete with natural ligands for binding . Comparative studies of antibodies targeting different domains could reveal epitope-specific effects on:

• Signaling pathway selectivity

• Resistance to antagonistic ligands

• Capacity for co-activation with Ang1

The systematic exploration of these structural parameters represents a frontier in Tie2 antibody development, potentially yielding next-generation therapeutics with tailored pharmacodynamic properties for specific disease contexts.

What are the technical challenges in developing highly specific cross-species reactive Tie2 antibodies?

Developing Tie2 antibodies with both high specificity and cross-species reactivity presents several technical challenges that researchers must navigate:

Epitope Conservation Analysis:
The degree of sequence conservation in Tie2 varies across domains and species. While some regions show high conservation, others display significant species-specific variations. Researchers must conduct detailed sequence alignments and structural analyses to identify epitopes that are:

• Conserved across target species (human, mouse, rat, non-human primates)

• Distinct from related receptors (particularly Tie1)

• Functionally relevant for antibody-mediated activation

The successful development of ASP4021 demonstrated that such epitopes exist, as this antibody showed remarkably consistent binding affinity across human, mouse, rat, and monkey Tie2 (KD values of 1.5 × 10^-9, 1.0 × 10^-9, 1.3 × 10^-9, and 1.5 × 10^-9 mol/L, respectively) .

Screening Methodology Optimization:
The hybridoma screening strategy significantly impacts cross-species reactivity outcomes. Advanced approaches include:

• Sequential multi-species screening cascades using cell-based ELISA with CHO cells expressing Tie2 from different species

• High-throughput binding assays with recombinant Tie2 extracellular domains from multiple species

• Functional screening in parallel using cells from different species to ensure consistent biological activity

Antibody Engineering Considerations:
When humanizing mouse-derived antibodies or engineering novel formats, researchers must balance species cross-reactivity with other design objectives:

• Framework selection during humanization can impact binding to non-human Tie2 variants

• CDR modifications may enhance human Tie2 binding while reducing cross-reactivity

• Tetravalent formats may compensate for lower affinity to certain species through avidity effects

Validation Across Model Systems:
Even when binding studies suggest good cross-reactivity, functional validation across species is essential. The observed difference between antibodies like ASP4021 (cross-reactive across species) and others like 15B8 (lacking rodent cross-reactivity) highlights the importance of early functional testing in cells from multiple species to guide development decisions.

These technical challenges underscore the value of sophisticated antibody engineering and comprehensive cross-species validation strategies in the development pipeline.

How might structural insights into Tie2-antibody complexes inform next-generation therapeutic development?

Structural insights into Tie2-antibody complexes provide critical guidance for next-generation therapeutic development, offering a rational basis for enhanced efficacy and specificity:

Clustering Mechanism Refinement:
The complex structures of Tie2 with hTAAB revealed that this antibody tethers preformed Tie2 homodimers into polygonal assemblies through specific binding to the Tie2 Fn3 domain . This structural insight demonstrates how antibodies can induce receptor clustering through mechanisms distinct from natural ligands. Future therapeutic designs could leverage this knowledge to:

• Engineer antibody variants that optimize the geometry of Tie2 clustering

• Develop bispecific formats that simultaneously engage Tie2 and co-receptors

• Create context-dependent clustering that responds to specific tissue environments

Epitope-Specific Signaling Modulation:
Structural studies indicate that antibodies targeting different Tie2 domains may induce distinct signaling outcomes. The binding of hTAAB to the Fn3 domain (distinct from the angiopoietin binding site) produces polygonal Tie2 clustering that is resistant to antagonism by Ang2 . This suggests that epitope selection could be strategically employed to design antibodies with:

• Enhanced function in high-Ang2 environments (such as tumor vasculature)

• Selective activation of specific downstream pathways

• Altered receptor internalization and recycling kinetics

Structure-Based Engineering Platforms:
Detailed structural data enables computational approaches to antibody optimization:

• In silico modeling of antibody-Tie2 interactions to predict affinity-enhancing mutations

• Molecular dynamics simulations to understand the conformational changes induced by antibody binding

• Structure-guided design of novel multivalent formats optimized for specific binding geometries

Translational Impact on Clinical Development:
Structural insights directly inform clinical development strategies by:

• Identifying biomarkers that predict response to specific antibody types based on their binding mode

• Guiding patient selection for clinical trials based on Tie2 polymorphisms that might affect antibody binding

• Enabling rational combination approaches based on structural understanding of how different agents interact with the Tie2 signaling complex

The structural characterization of polygonal Tie2 clustering induced by hTAAB represents a significant advance in our understanding of antibody-mediated receptor activation, providing a template for designing next-generation therapeutics with enhanced efficacy and specificity profiles.